Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update
February 8, 2021 4:05 PM ESTFinancial Highlights, 2021 Revenue Guidance and Legal Update
Preliminary 2020 revenue $353.9 million, compared to $306.5 million in 2019Preliminary fourth quarter revenue $85.7 million, compared to $87.9 million in fourth quarter 20192021 revenue guidance $375 - 405 millionPreliminary 2020 fully diluted GAAP net income $0.85 per share, compared to $0.77 per share in 2019Preliminary fourth quarter fully diluted GAAP net income $0.20 per share, compared to $0.24 per share in fourth quarter 2019Preliminary cash and investments at December 31, 2020 of $476.9 million, an increase of $161.6 million from December 31, 2019Patent Trial and Appeals Board... More